| | | | | | SynVax Pharmaceuticals, Inc.
| | | | | | | | SynVax Pharmaceuticals, Inc., in engaged in biopharmaceutical research in infectious diseases, cardiovascular diseases and pain management. The company intends to develop and assist in the commercialization of several new classes of therapeutic products.
The key chronic disease states for which the company’s products are designed to provide treatment include: (i) fungal infections in patients who are immunosuppressed as a result of HIV infection, cancer therapy or bone marrow and organ transplantation, and pregnancy; (ii) bacterial infection due to Staphylococcus Mycobacterium tuberculosis, and Bacillus anthracis; (iii) edematous conditions e.g., congestive heart failure (CHF), hypertension, diabetes insipidus etc., using water diuretics; and (iv) chronic and neuropathic pain.
Management contents that the company has, at present, at least five significant discoveries ready for development with several more in the pipeline. These products are based on advanced peptide structure-function analyses and expertise in peptide synthesis. The company has received a U.S.
patent for one product and others pending. To date, management has obtained National Institutes of Health grants totaling $1.8 million.
Management’s strategy is to optimize the value of its drug candidates by completing at least Phase II clinical trials.
The company believes it has identified significant opportunities in the drug development area. Through its research, management believes that the drug leads discovered by the company have multi-billion dollar market potential and anticipates it can conservatively claim at least 20 to 25 percent of the targeted markets. Management estimates the total value of these niche markets to exceed $10 billion annually. |
|
|
|
|
|
|
|
|
|
| | | | | |
| |
|
|
|
|
.gif)
